OvaScience Inc (OVAS) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.80 earnings per share for the quarter, missing the analyst consensus estimate by $-0.09. Analysts had a consensus of $-0.71. The company posted revenue of $.15 million in the period, compared to analysts expectations of $.14 million. The company’s revenue was up 630.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.65 EPS.
OvaScience Inc closed down -0.77 points or -10.12% at $6.84 with 4,16,545 shares getting traded on Wednesday. Post opening the session at $7.5, the shares hit an intraday low of $6.685 and an intraday high of $7.7 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Mar 23, 2016, Michelle Dipp (CEO) purchased 59,800 shares at $10.25 per share price. According to the SEC, on Mar 23, 2016, Richard Aldrich (director) purchased 59,800 shares at $10.25 per share price. On Oct 7, 2015, Jeffrey E Young (CFO) purchased 3,450 shares at $10.70 per share price, according to the Form-4 filing with the securities and exchange commission.
OvaScience Inc. is a global fertility company. The Company is focused on the discovery development and commercialization of new fertility treatments based on egg precursor or EggPC cells which are immature egg cells found in the protective outer layer of a woman’s own ovaries. With the Company’s AUGMENT treatment energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a woman’s own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.